The Use of Tocilizumab in the Management of Patients Who Have Severe COVID-19 With Suspected Pulmonary Hyperinflammation
Status:
Recruiting
Trial end date:
2021-05-08
Target enrollment:
Participant gender:
Summary
Title: The use of Tocilizumab in the management of patients who have severe COVID-19 with
suspected pulmonary hyperinflammation.
This is a study designed to assess the therapeutic value of intravenous tocilizumab
administered as single 8mg/Kg dose in patients affected by SARS-CoV2 infection with a
pulmonary manifestation causing hypoxia. Aim of the study is to test the hypothesis that
anti-IL6 treatment can be effective in reducing the virus-induced cytokine storm, blocking
deterioration of lung function or even promoting a rapid improvement of clinical conditions,
preventing tracheal intubation and/or death.
This drug will be administered to those patients entering the ICU with severe acute
respiratory failure COVID-19 disease. The endpoints are death and duration of
hospitalization. The patients will be assessed with surrogate markers determining the level
of the cytokine storm.